ALK-Abelló is a global specialty pharmaceutical company focused on the treatment and management of allergies. The company develops, manufactures, and markets allergy immunotherapy treatments and diagnostics, utilizing natural allergens such as grass pollen and house dust mites. Its product portfolio includes sublingual immunotherapy tablets, sublingual drops, adrenaline auto-injectors, and a nasal adrenaline spray for anaphylaxis. ALK-Abelló serves patients and healthcare professionals in multiple markets worldwide, with production sites in the USA, Spain, France, and Denmark. The company operates under the legal name ALK-Abelló, having merged with Spanish company Abelló, while its operating brand is ALK, formerly known as Allergologisk Laboratorium København. It was founded in 1923 by pharmacist Peter Barfod and physician Kaj Baagøe. Notable partnerships include a strategic tablet supply partnership with Catalent. The company's digital patient engagement platform is klarify.me.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Drug Manufacturers - Specialty & Generic Homepage alk.net
Sector Healthcare IR page ir.alk.net
Tags
allergy immunotherapy, sublingual tablets, adrenaline spray, anaphylaxis treatment, allergy diagnostics, respiratory allergies, food allergies, specialty pharma, ALK, ALK-Abelló, Abelló, Allergologisk Laboratorium København, klarify.me, EURneffy
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 20.3%
ROI 18.1%
ROIC 25.1%
Profit margin 19.0%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) 52.9%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock —
Diluting (TTM) —
Debt/Equity 2.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 89
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 6.312B 5.537B 4.824B 4.511B 3.916B
Net profit 1.197B 815M 486M 335M 219M

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

October 19, 2026

PDF Version

Intern viden

  • Fase 3-studiet med ACARIZAX® i kinesiske patienter opfyldte det primære formål og viste effekt på linje med tidligere studier efter kun 24-28 ugers behandling.

  • ACARIZAX®var sikker og veltolereret, i overensstemmelse med data fra tidligere studier gennem mere end ti år.

  • ALK vil nu sammen med sin partner GenSci forberede indsendelsen af registreringsansøgningen vedrørende ACARIZAX® i Kina. Ansøgningen forventes indsendt i første halvdel af 2027.

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) har i dag annonceret positive resultater for fase 3-studiet, der evaluerer effekt og sikkerhed af ALK's sublinguale immunterapi-tablet (”SLIT”), ACARIZAX®, hos kinesiske patienter i alderen 12-65 år med allergisk rhinitis/rhinokonjunktivitis, med eller uden astma forårsaget af husstøvmider. Studiet var designet til at vise en trend i overensstemmelse med tidligere kliniske studier foretaget med ACARIZAX® uden for Kina.

Deltagerne blev behandlet i 24-28 uger med enten ACARIZAX® eller placebo. Det primære endepunkt var den gennemsnitlige daglige totale kombinerede rhinitis-score (”TCRS”) i den primære effektvurderingsperiode. TCRS blev målt ved registrering af allergisymptomer og brug af allergimedicin i de sidste fire uger af behandlingen.

Studiet opfyldte sit primære formål. Den absolutte behandlingsforskel i TCRS var 1,11 (hvor den nedre ende af 95%-konfidensintervallet var over nul; den relative behandlingsforskel var 19,1%) til fordel for ACARIZAX® sammenlignet med placebo og lå dermed væsentligt over det foruddefinerede succeskriterium, som var aftalt med de kinesiske myndigheder. Studiet viste desuden, at behandlingen var sikker og veltolereret i både den unge og den voksne aldersgruppe, i overensstemmelse med den sikkerhedsprofil, der er påvist i tidligere studieresultater.

Studiet var vellykket på tværs af endepunkter og centrale mål for studiets gennemførelse, herunder fastholdelse af deltagere og behandlingscompliance:

  • Der blev observeret en gunstig behandlingsforskel i den samlede population og i både den unge og den voksne aldersgruppe

  • Tidligt indsættende effekt blev påvist fra uge 8 i den første TCRS-effektvurderingsperiode

  • Da deltagerne blev bedt om at sammenligne deres rhinitis-symptomer før og efter behandling, var deltagere behandlet med ACARIZAX® 4,3 gange mere tilbøjelige til at have det bedre ved studiets afslutning end deltagere, der fik placebo

  • Studiet var vellykket med høj behandlingscompliance og lavt frafald blandt deltagerne.

ALK’s direktør for forskning og udvikling, Jacob Glenting, siger: “Resultaterne af vores kliniske fase 3-studie er robuste og helt på linje med mere end ti års data for vores husstøvmidetablet, og de bekræfter, at den både er effektiv og sikker for kinesiske patienter og kan gøre en reel forskel for allergikere i Kina. Sammen med vores partner GenSci vil vi nu fortsætte dialogen med de kinesiske sundhedsmyndigheder for at søge regulatorisk godkendelse, så vi kan gøre behandlingen tilgængelig for de millioner af mennesker i Kina, som lever med husstøvmideallergi.”

Studiet var et randomiseret, dobbeltblindet, placebokontrolleret, multicenter, fase 3-registreringsstudie i Kina, hvor 327 patienter fik behandling med ACARIZAX® eller placebo én gang dagligt i 24-28 uger. Studiet var designet til at generere kinesiske kliniske data, som sammen med eksisterende globale data forventes at understøtte lokal regulatorisk godkendelse af ACARIZAX®.

Under forudsætning af godkendelse fra de kinesiske myndigheder vil ACARIZAX® blive tilføjet GenScis portefølje under den partnerskabsaftale, der blev annonceret i september 2025 (selskabsmeddelelse nr. 15/2025).

Kina er det land i verden, hvor flest mennesker lider af husstøvmideallergi. Alligevel er markedet fortsat markant underpenetreret med anslået mere end 100 millioner berørte og færre end 1 million mennesker, der på nuværende tidspunkt modtager behandling med allergi-immunterapi.

Resultaterne påvirker ikke ALK's finansielle forventninger til 2026.

ALK-Abelló A/S

For yderligere oplysninger kontakt venligst: Investor Relations: Per Plotnikof, tlf. 4574 7527, mobil 2261 2525 Presse: Maiken Riise Andersen, tlf. 5054 1434

Denne meddelelse indeholder intern viden. Dette er oplysninger, som ALK-Abelló A/S er forpligtet til at offentliggøre i henhold til EU's markedsmisbrugsforordning.

Om ALK ALK er en global, specialiseret medicinalvirksomhed med fokus på allergi. ALKs aktiviteter dækker hele værdikæden for udvikling, sourcing, produktion og markedsføring af en bred portefølje af produkter til diagnosticering og behandling af luftvejsallergier og alvorlige allergiske reaktioner (anafylaksi) hos både børn og voksne. Virksomheden har hovedkvarter i Hørsholm, beskæftiger omkring 2.800 mennesker over hele verden og er noteret på Nasdaq Copenhagen. Find mere information på www.alk.net.

Om Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci) GenSci er en førende biofarmaceutisk virksomhed i Kina, der specialiserer sig i pædiatri og kvinders sundhed. Derudover er GenSci aktiv inden for andre områder: endokrinologi, metaboliske sygdomme, immunologi/respiratorisk og onkologi. Virksomheden har over 8.000 ansatte og integrerer forskning, udvikling, produktion og markedsføring af innovative terapier i sin værdikæde. Virksomheden blev etableret i 1997, er et datterselskab af Changchun High-Tech Industries (Group) og har hovedkontor i Changchun, Kina. Find mere information på www.genscigroup.com/en.

Den danske meddelelse er en oversættelse af den engelske meddelelse. Den engelske meddelelse er den til enhver tid gældende version.

Vedhæftet fil

Email Alerts](https://ir.alk.net/da/email-alerts)

  • [Downloads

Downloads](https://ir.alk.net/da/download-library)

  • [RSS

RSS](https://ir.alk.net/da/rss)

  • Udskriv

Udskriv

  • Del

Del

  • [English

English](https://www.alk.net/)

  • Søg

Søg

facebook sharing button

linkedin sharing button

twitter sharing button

email sharing button

October 19, 2026

PDF Version

Inside Information

  • Phase 3 trial with ACARIZAX® in Chinese participants met the primary objective and showed efficacy in line with previous trials, after only 24-28 weeks of treatment.

  • **ACARIZAX® was shown to be safe and well-tolerated,**consistent with data obtained in previous trials over the past 10+ years.

  • ALK will now work with its partner GenSci to file for regulatory approval of ACARIZAX® in China. Filing is expected in first half of 2027.

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced positive topline results from the phase 3 bridging trial evaluating the efficacy and safety of its house dust mite (‘HDM’) sublingual immunotherapy (‘SLIT’) tablet, ACARIZAX®, in Chinese participants aged 12 - 65 years with HDM allergic rhinitis/rhinoconjunctivitis, with or without asthma. The trial was designed to show a consistent trend with the previous clinical trials conducted with ACARIZAX® outside China.

Participants were treated for 24-28 weeks with either ACARIZAX® or placebo. The primary endpoint was the average daily total combined rhinitis score (‘TCRS’) during the primary efficacy assessment period. The TCRS was measured by recording the allergy symptoms and pharmacotherapy use in the last 4 weeks of treatment.

The trial achieved its primary objective. The absolute treatment difference of the TCRS was 1.11 (with a lower bound of the 95% confidence interval exceeding zero; the relative difference was 19.1%) favouring ACARIZAX® over placebo, thereby substantially exceeding the predefined success criterion that was agreed with the Chinese authorities. The trial also demonstrated the treatment to be safe and well-tolerated in both the adolescent and adult age groups in line with the safety profile established with previous trial results.

The trial performed well across endpoints as well as key measures of trial conduct, including participant retention and treatment compliance:

  • A favourable treatment difference was observed in the overall population, and in both adult and adolescent subgroups

  • Early onset of efficacy was demonstrated from week 8, during the first TCRS efficacy assessment period

  • When asked to compare their rhinitis symptoms before and after treatment, participants treated with ACARIZAX® were 4.3 times more likely to feel better at the end of the trial than those who received placebo

  • The trial was executed successfully, with high treatment compliance and low participant dropout rates.

Jacob Glenting, EVP and Head of Global R&D, says: “The results of our phase 3 clinical trial in China are robust and highly consistent with more than a decade of data on our house dust mite tablet, confirming that it is both efficacious and safe for Chinese patients and can make a real difference for allergy sufferers in China. Together with our partner GenSci, we will now continue the dialogue with the Chinese health authorities to seek regulatory approval, so that we can make this treatment available to the millions of people in China living with house dust mite allergy.”

The trial was a randomised, double-blind, placebo-controlled, multi-site phase 3 registration trial conducted in China, enrolling 327 participants who received a once-daily treatment with ACARIZAX® or placebo for 24-28 weeks. The trial was designed to generate Chinese clinical data which, together with existing global data, is expected to support local regulatory approval of ACARIZAX®.

Subject to approval by the Chinese authorities, ACARIZAX® will be added to GenSci's portfolio under the partnership agreement announced in September 2025 (company release No 15/2025).

Worldwide, China is the country with the highest number of people suffering from house dust mite allergy. Yet the market remains significantly underpenetrated with estimated more than 100 million affected and less than 1 million people currently receiving allergy immunotherapy treatment.

The trial results do not affect ALK's financial guidance for 2026.

ALK-Abelló A/S

October 12, 2026

PDF Version

  • New UK comparative study data assessing patient preferences between trainer devices suggest EURneffy® is viewed as less burdensome than adrenaline auto-injectors (AAIs)1

  • After trying both trainer devices, patients rated EURneffy® significantly more compact, convenient and independence-enabling to carry than AAIs across four patient-identified carriage measures2

  • In a Canadian comparative study assessing usability of trainer devices, participants found EURneffy® significantly easier to use than an AAI across all nine measures assessed3

  • Preference for EURneffy® was consistent across the populations studied, including participants with severe allergy (adults and children), their caregivers, and participants and caregivers with no prior experience of adrenaline devices1-3

New scientific data suggest that fear, stress and the physical bulk of AAIs are significant, often underappreciated barriers that may prevent many people at risk of anaphylaxis from consistently carrying or using their emergency anaphylaxis treatment.1-3 Findings from studies conducted by ALK were presented at the 2026 British Society for Allergy and Clinical Immunology (BSACI) Conference in Newport, Wales.

| Presenting author | Abstract title and number | Abstract number | Date and time |

| Dr Pamela Ewan | The emotional burden of adrenaline devices: How fear, stress, and worry shape Patients' experience of autoinjector and nasal spray | (A046) | Monday 12 October 2026, 11:00-11:45 (Poster Walk B) |

| Dr Pamela Ewan | Patient-identified carriage constructs favour a nasal adrenaline spray over an autoinjector: Compactness, convenience, and independence | (A077) |

| Dr Shelley Dua | A simpler emergency device? Higher ease-of-use ratings for a nasal adrenaline spray than an adrenaline autoinjector in a Canadian comparative study | (A086) |

Anaphylaxis is one of the most severe forms of allergic reaction, which requires immediate treatment with adrenaline.4-7 Despite clinical recommendations, research shows that approximately half of those living with a severe allergy did not administer their AAI when needed in an emergency, and nearly half of those at risk of anaphylaxis do not regularly carry their AAIs.8,9

In a UK comparative study involving 90 participants, this analysis focused on a subgroup of 60 participants (20 adult patients, 20 caregivers, 20 new patients), who completed rating scales developed from patients’ own descriptions of living with severe allergy.1 EURneffy®, the first needle-free adrenaline-based product, was rated significantly less burdensome than AAIs on all four patient-generated scales (p<0.001).1 EURneffy® was commonly described as calming to use, comforting to carry, easy for others to help with and being relaxed about correct storage.1

A second analysis of the same UK study further examined how participants felt about carrying their adrenaline device. EURneffy® was rated more likely to be carried than AAIs on measures including compactness, convenience, independence and control over who knows they carry medication for a severe allergy (p<0.001).2

“What's compelling about our UK study findings is that the rating scales were built directly from patients describing, in their own words, what it's really like to carry anaphylaxis emergency medication every day,” said Dr Pamela Ewan, Author and Consultant Allergist at Addenbrooke's Hospital and Associate Lecturer at the University of Cambridge Clinical School. “The nasal adrenaline spray was easier to carry, less daunting to use, and offered greater independence and discretion. For teenagers and young adults especially, these factors could play an important role in helping them feel confident carrying and using their anaphylaxis medication when they need it most.”

In another comparative study of EURneffy® and AAI trainer devices involving 120 participants in Canada, an analysis of 90 participants showed that EURneffy® was rated significantly easier to use than an AAI across all measures assessed (p<0.001).3 Participants rated EURneffy® more intuitive to use (94% vs 58%), more usable without help (98% vs 84%), when feeling unwell (94% vs 63%), and regardless of surroundings (97% vs 78%), as well as easier to remember after a single demonstration (96% vs 70%), more comfortable to handle (96% vs 66%), and felt more confident using it for the first time (89% vs 58%) than an AAI.3

“Patients should be educated about the importance of carrying an adrenaline device and being able to use it in an emergency,” said Flora Beiche-Scholz, EVP Commercial Operations Europe, ALK. “These data reinforce our commitment to understanding and addressing the diverse needs of people living with severe allergies, now and in the future, including the practical and emotional aspects highlighted by these findings”.

ALK-Abelló A/S

Prompts

ALK-Abelló (ticker ALK-B), listed in Denmark.

ETFs Holding ALK-Abelló

ETF Weight in ETF Shares Market value As of
OAIM 0.86% 103,562 $ 3.36M Aug 31, 2026
DFIS 0.08% 133,291 $ 4.909M Nov 12, 2026
DFIC 0.03% 123,710 $ 4.556M Nov 12, 2026
DFSI 0.03% 8,674 $ 319.473K Nov 12, 2026
DFAX 0.03% 84,416 $ 3.109M Nov 12, 2026
DFAI 0.01% 63,368 $ 2.334M Nov 12, 2026
AVDE 0.01% 47,606 $ 1.768M Nov 16, 2026
AVDS 0.01% 520 $ 19.312K Nov 16, 2026